- RecruitingPHASE3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This study looks at a medicine called abrocitinib for children aged 2 and older with moderate to severe eczema. It checks how safe and effective it is over the long term, with some children having used it before and others trying it for the first time.
For: Atopic DermatitisUnited States · China · Germany - Recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
For: Atopic Dermatitis · PsoriasisGermany - RecruitingPHASE3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This study is testing a new medicine, abrocitinib, for children aged 6 to under 12 who have moderate-to-severe eczema. We want to see if it improves their skin and is safe. Some children will get the medicine, others a pretend one.
For: EczemaUnited States · China · Germany